insights_auto
Kodėl „WUXI06“ sumažėjo 5,31%?
Įsigilintichevron_right
WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
5,35 THB
arrow_downward
−5,31%(−0,30) 1 D.
10-14, 13:19:25 GMT+7 · THB
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „WUXI06“ įžvalgos...
Atidaryti
5,45 THB
Aukšta
5,45 THB
Žema
5,35 THB
Rinkos kapitalizacija
204,77 mlrd.
Vid. kiekis
99,31 tūkst.
Apimtis
61,48 tūkst.
52 sav. aukšta
6,25 THB
52 sav. žema
3,02 THB
Neapmokėtos akcijos
4,12 mlrd.
Darbuotojų skaičius
15 tūkst.
Atidaryti
5,45 THB
Aukšta
5,45 THB
Žema
5,35 THB
Rinkos kapitalizacija
204,77 mlrd.
Vid. kiekis
99,31 tūkst.
Apimtis
61,48 tūkst.
52 sav. aukšta
6,25 THB
52 sav. žema
3,02 THB
Neapmokėtos akcijos
4,12 mlrd.
Darbuotojų skaičius
15 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Smartkarma
·
prieš 4 dienas
Wuxi Biologics (Cayman)'s Stock Price Stands at 53.85 HKD, Experiences Minor Dip of 0.46%
Profilis
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Apie „Wuxi Biologics (Cayman) Inc. KKPS DR“
Generalinis direktoriusZhisheng Chen
Darbuotojai14,7 tūkst.
Įkurta2010
Pagrindinė būstinė-
Sektorius-
Svetainėwuxibiologics.com